Log in to save to my catalogue

Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with decompensated cirrhosis...

Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with decompensated cirrhosis...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2479577432

Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with decompensated cirrhosis: a Japanese real-world multicenter study

About this item

Full title

Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with decompensated cirrhosis: a Japanese real-world multicenter study

Publisher

Singapore: Springer Singapore

Journal title

Journal of gastroenterology, 2021-01, Vol.56 (1), p.67-77

Language

English

Formats

Publication information

Publisher

Singapore: Springer Singapore

More information

Scope and Contents

Contents

Background
Real-world data on the efficacy and safety of sofosbuvir plus velpatasvir (SOF/VEL) treatment for patients with hepatitis C virus (HCV)-related decompensated cirrhosis are limited in Japan.
Methods
A total of 190 patients with compensated (108) or decompensated (82) cirrhosis who initiated direct-acting antiviral (DAA) treatment...

Alternative Titles

Full title

Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with decompensated cirrhosis: a Japanese real-world multicenter study

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_journals_2479577432

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2479577432

Other Identifiers

ISSN

0944-1174

E-ISSN

1435-5922

DOI

10.1007/s00535-020-01733-4

How to access this item